Navigation Links
Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
Date:2/28/2013

Sacramento (PRWEB) February 28, 2013

Today at the State Capitol, Assemblyman Marc Levine (D-San Rafael), in partnership with the California Healthcare Institute (CHI), presented a House resolution recognizing Feb. 28, 2013 as Rare Disease Day.

“On this 30th anniversary of the Orphan Drug Act, we recognize the need for continued incentives for biomedical innovators to bring much needed treatments to patients in need,” Levine said.

It is estimated that there are 7,000 diseases considered rare in the U.S. affecting almost 30 million Americans or about 1 in 10 people. Most rare and ultra-rare diseases have no treatment.

In 1983, Congress enacted the Orphan Drug Act to provide incentives for medical pharmaceutical and product developers to focus on treatments for victims of rare diseases. Since that time, there have been more than 2,700 products studied as possible treatments for rare diseases, and more than 400 of those have been approved by the U.S. Food and Drug Administration. Most of these were for diseases that had no approved treatment.

A disease is considered rare in the U.S. if it affects fewer than 200,000 people. Approximately 50 percent of the people affected by rare diseases are children. Even more prominent are ultra-rare diseases that affect only a few thousand individuals.

Patients with rare diseases and ultra-rare diseases are frequently misdiagnosed or are undiagnosed. Few drug companies conduct research into rare diseases since it is difficult to recover the costs of developing treatments for small, geographically dispersed populations.

BioMarin Pharmaceuticals Inc., based in Novato, Calif., is a pioneer in the area of rare disease research. Dedicated to having a meaningful impact in the lives of underserved patients suffering from diseases that are often ignored, BioMarin has successfully brought four therapies for rare genetic diseases to market. The company has five additional therapies in various phases of clinical trials and multiple pre-clinical programs devoted to treating additional rare diseases. Due to their global success of providing effective therapies, BioMarin has nearly doubled their number of employees in the last five years.

“CHI encourages research and development efforts dedicated to advancing new treatments for patients suffering from rare diseases,” said CHI President and CEO David L. Gollaher, Ph.D. “Rare Disease Day serves as a reminder that while millions of patients have benefited from new treatments, many more remain in need of timely and accurate diagnosis, along with adequate treatment options.”

About CHI
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is http://www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10480977.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
3. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
4. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
5. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
6. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
7. Fusion presents low proliferation risk, experts conclude
8. ODT Forum Presents Regenerative Technologies
9. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
10. Cardium Presents First Quarter 2012 Financial Results and Recent Developments
11. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 ... the trading session at 5,817.69, down 0.07%; the Dow ... 20,656.58; and the S&P 500 closed at 2,345.96, marginally ... 4 sectors closed in green, 4 sectors finished in ... This Friday, Stock-Callers.com has initiated reports coverage on the ...
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... ... 23, 2017 , ... Ellen Matloff, president and CEO of ... as a 2017 Women of Innovation® finalist. Matloff will be among several women ... The dinner recognizes women accomplished in science, technology, engineering and math (STEM), along ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... closer look at four equities in the Biotech industry: ... EYEG), Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus ... March 21 st , 2017, Credit Suisse upgraded its rating ... stocks by downloading their free report at: ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), ... published by MarketsandMarkets, the market is expected to be worth USD 18.98 billion ... Continue Reading ... ...      (Logo: ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
Breaking Biology News(10 mins):